| Methods |
3‐week single‐blind placebo run‐in; inclusion criteria= sitting DBP 95‐104 mm Hg after run‐in; 6‐week double‐blind treatment |
| Participants |
Perindopril 4 mg: n=253(130 males,123 females); mean age=59.3(11.1) years; baseline SBP=161.7(17.5) mm Hg, DBP=99.4(4.8) mm Hg, HR=78.5(14.3) bpm;
Placebo: n=237(133 males,104 females); mean age=59.1(10.8) years; baseline SBP=160.3(16.9) mm Hg, DBP=99.5(4.6) mm Hg, HR=79.3(13.9) bpm |
| Interventions |
Perindopril 4 mg once daily;
Placebo;
administered in the morning |
| Outcomes |
Trough sitting SBP/DBP using automatic device;
HR |
| Notes |
BP change and SD of change not reported, endpoint BP and SEM reported, calculated endpoint SD from N and endpoint SEM, imputed endpoint SD for SD of change; BP data from Table III, p. 129; Jadad score=3; funding source= Servier |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
